Sex-Specific Protective Effects of APOE ε2 on Cognitive Performance.


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 13 05 2020
pubmed: 30 9 2020
medline: 16 7 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

Apolipoprotein E (APOE) has an important role in the multiple trajectories of cognitive aging. However, environmental variables and other genes mediate the impact of APOE on cognition. Our main objective was to analyze the effect of APOE genotype on cognition and its interactions and relationships with sex, age, lipid profile, C-reactive protein, and Brain-derived neurotrophic factor (BDNF) genotype in a sample of 648 healthy participants over 50 years of age with a comprehensive neuropsychological assessment. Our results showed that APOE ε2 carriers performed better in the Verbal Memory (p = .002) and Fluency Domains (p = .001). When we studied the effect of sex, we observed that the beneficial effect of APOE ε2 on the normalized values of these cognitive domains occurred only in females (β = 0.735; 95% confidence interval, 0.396-1.074; p = 3.167·10-5 and β = 0.568; 95% confidence interval, 0.276-0.861; p = 1.853·10-4, respectively). Similarly, the sex-specific effects of APOE ε2 were further observed on lipidic and inflammation biomarkers. In the whole sample, APOE ε2 carriers showed significantly lower levels of total cholesterol, low-density lipoprotein cholesterol, and C-reactive protein. These differences were found only among females. Furthermore, total cholesterol and low-density lipoprotein cholesterol mediated the protective effect of APOE ε2 on cognition in the whole sample and total cholesterol in females, providing candidate physiological mechanisms for the observed genetic effects. Our results show that the neuroprotective role of APOE ε2 in cognition varies with sex and that the lipidic profile partially mediates this protection. Age-related cognitive and functional decline is a continuous biological process with different cognitive trajectories (1). Complex interactions between heritability, environmental influence, and cognitive functions in aging have been highlighted (2). In particular, genetic differences explain around 15%-25% of the variance in life expectancy (3). Therefore, the identification of susceptibility genes and their biological effects on cognitive aging is required to establish interindividual differences in this process and promote early personalized interventions to delay cognitive decline and minimize the financial burden of aging in the health care system.

Identifiants

pubmed: 32992326
pii: 5913014
doi: 10.1093/gerona/glaa247
doi:

Substances chimiques

Apolipoprotein E2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-49

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Noemí Lamonja-Vicente (N)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.

Rosalia Dacosta-Aguayo (R)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Jorge López-Olóriz (J)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Unidad de Trastornos del Aprendizaje (UTA), Fundación Josep Finestres (FJF), Barcelona, Spain.

Laia Prades-Senovilla (L)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Francesca Roig-Coll (F)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Alba Castells-Sánchez (A)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.

Juan José Soriano-Raya (JJ)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.

Inmaculada Clemente (I)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.

Júlia Miralbell (J)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.

Maite Barrios (M)

Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.
Department of Social Psychology and Quantitative Psychology, Universitat de Barcelona, Spain.

Elena López-Cancio (E)

Departamento de Neurología, Unidad de Ictus Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Cynthia Cáceres (C)

Department of Neuroscience, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Juan Francisco Arenillas (JF)

Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain.
Neurovascular Research Laboratory, Instituto de Biología y Genética Molecular, Universidad de Valladolid-Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Mónica Millán (M)

Department of Neuroscience, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Pere Torán (P)

Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Mataró, Spain.

Guillem Pera (G)

Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Mataró, Spain.

Rosa Fores (R)

Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Mataró, Spain.

Maria Teresa Alzamora (MT)

Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Mataró, Spain.

Maria Mataró (M)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.

Marc Via (M)

Department of Clinical Psychology and Psychobiology, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH